5 Drugs Stocks On The Rise

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.1%) at 15,256 as of Monday, June 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,353 issues advancing vs. 1,578 declining with 107 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.1%. A company within the industry that increased today was Novo Nordisk A/S ( NVO), up 0.75. On the negative front, top decliners within the industry include Dynavax Technologies Corporation ( DVAX), down 35.63, and Alexion Pharmaceuticals ( ALXN), down 1.75.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. ACADIA Pharmaceuticals ( ACAD) is one of the companies pushing the Drugs industry higher today. As of noon trading, ACADIA Pharmaceuticals is up $2.91 (17.11) to $19.92 on heavy volume Thus far, 9.1 million shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $17.05-$20.09 after having opened the day at $17.29 as compared to the previous trading day's close of $17.01.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.5 billion and is part of the health care sector. Shares are up 256.3% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full ACADIA Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Novartis ( NVS) is up $0.47 (0.65) to $72.45 on average volume Thus far, 739,457 shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $71.78-$72.63 after having opened the day at $72.05 as compared to the previous trading day's close of $71.98.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $175.6 billion and is part of the health care sector. The company has a P/E ratio of 18.4, above the S&P 500 P/E ratio of 17.7. Shares are up 13.7% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.60 (1.51) to $40.08 on average volume Thus far, 2.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $39.46-$40.11 after having opened the day at $39.49 as compared to the previous trading day's close of $39.49.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.1 billion and is part of the health care sector. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.48 (0.57) to $85.39 on light volume Thus far, 3.7 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10.0 million shares. The stock has ranged in price between $84.73-$85.71 after having opened the day at $85.01 as compared to the previous trading day's close of $84.91.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $237.2 billion and is part of the health care sector. The company has a P/E ratio of 23.0, above the S&P 500 P/E ratio of 17.7. Shares are up 21.1% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Merck ( MRK) is up $0.47 (0.98) to $48.66 on average volume Thus far, 7.9 million shares of Merck exchanged hands as compared to its average daily volume of 18.3 million shares. The stock has ranged in price between $48.44-$48.89 after having opened the day at $48.65 as compared to the previous trading day's close of $48.19.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $146.8 billion and is part of the health care sector. The company has a P/E ratio of 24.8, above the S&P 500 P/E ratio of 17.7. Shares are up 17.7% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Merck a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Stocks Slide on Renewed Trade War Concerns

Stocks Slide on Renewed Trade War Concerns

Emerging Markets Get Pounded by Global Trade Concerns

Emerging Markets Get Pounded by Global Trade Concerns

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies